To evaluate whether screening for familial hypercholesterolaemia (FH) is appropriate; to determine which system of screening is most acceptable and cost-effective; to assess the deleterious psychosocial effects of genetic and clinical screening for an asymptomatic treatable inherited condition; and to assess whether the risks outweigh the potential benefits of screening.
Study selection Study designs of evaluations included in the review
No inclusion criteria for the study designs were specified. The designs considered ranged from randomised controlled trials (RCTs) to secondary literature without any empirical data.
Specific interventions included in the review
Studies were eligible for the review if they looked at the mortality and morbidity associated with FH, the screening and treatment of FH since the introduction of statins, or the safety and efficacy of statin use. Studies of resin therapy in children were also eligible for inclusion. Pre-treatment publications were considered seperately.
For the analysis of the psychosocial effects of genetic screening, studies that looked at screening for modifiable inherited conditions were considered.
Reference standard test against which the new test was compared
The review did not include any diagnostic accuracy studies that compared the performance of the index test with a reference standard of diagnosis.
Participants included in the review
No specific inclusion criteria for the participants were selected. The included studies were of patients with FH, patients being screened for FH, patients being treated for FH, and patients being treated with statin for other reasons than FH.
Outcomes assessed in the review
The mortality and morbidity associated with FH, and the effectiveness and cost of both treatment and screening, were addressed in the review.
How were decisions on the relevance of primary studies made?
performed the validity assessment.
Data extraction
The authors did not state how the data were extracted for the review, or how many reviewers performed the data extraction.
Details of the study design and results were presented for mortality, morbidity and treatment effect.
For the empirical data studies on the psychosocial effects of screening, details on the following were presented: key issues addressed, study design, conclusions, the number and type of patients, comments or problems, and the relevance to an FH screening policy. The setting, method and results, together with the validity assessment, were accessible in an appendix. Information from secondary papers was also extracted: main points, potential benefits, potential disadvantages, and recommendations and comments.
For the cost-effectiveness studies of statin treatment, the hypothesis, data sources and results were noted.
Methods of synthesis
How were the studies combined? With the exception of the cost data, the studies were synthesised in the narrative.
How were differences between studies investigated?
The studies were presented according to their design and topic groups.
Results of the review
Seventeen studies of morbidity and mortality in adults since the introduction of statins and 5 pre-treatment studies were included; 8 papers on children were also included. Thirty-nine papers looked at the psychosocial effects of genetic screening. Of these, only 16 reported primary data. Four of the empirical studies of psychosocial effects were RCTs. Eight studies presenting cost-effectiveness data for treatment with statins were also reported.
Effectiveness.
The authors stated that FH is a life-threatening condition with a long presymptomatic state. Tests to diagnose FH are reasonably reliable and acceptable, while treatment with statins improves the prognosis substantially. The authors therefore believed that it is appropriate to consider systematic screening for the condition.
Psychosocial effects of screening.
Only a few papers that addressed the psychosocial effects of screening were located and their quality was poor. Problems with labelling and discrimination were hypothesised in the literature, but there were few empirical data to support these hypotheses. The review found no evidence of mental health or social functioning problems in adults following a diagnosis of FH, but there was weak evidence that children react negatively to the diagnosis. The authors stated that it is possible that diagnosis in adults may make it more difficult for them to get life insurance (statement based on opinions expressed in the included publications). The studies reported fear of discrimination as a barrier to screening. The literature supported the idea of counselling at the time of screening, but the nature of the counselling was poorly described and there were no data to support its effectiveness.
Cost information
A model investigating the relative cost and effectiveness of different forms of population screening (universal or opportunistic) and case-finding screening (screening relatives of FH patients) was constructed. The model assumed an identifying stage (identifying cases with cholesterol levels fitting the diagnostic criteria of FH) and further established the diagnosis on clinical signs and a family history of coronary disease, or through carrying out genetic tests. The incremental cost per year of life gained was applied as the cost-effectiveness measure. The most cost-effective strategy was case finding amongst relatives of FH cases; the least cost-effective was universal systematic screening (except for when targeted at 16 year olds).
Screening patients admitted to hospital with premature myocardial infarction was relatively cost-effective. Screening was least cost-effective in men aged over 35 years as the gains in life expectancy are small. Following the modelling results, a combination of strategies should be applied.
